Cediranib

Generic Name: Cediranib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₇FN_₄O_₃

CAS Number: 288383-20-0

Unique Ingredient Identifier: NQU9IPY4K9

Background: The novel indole-ether quinazoline Cediranib is a highly potent (IC < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.

Indication: For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Phase 2

Active, not recruiting

Conditions: Fallopian Tube Mucinous Adenocarcinoma
Ovarian Seromucinous Carcinoma
Platinum-Refractory Fallopian Tube Carcinoma
Platinum-Refractory Ovarian Carcinoma
Platinum-Refractory Primary Peritoneal Carcinoma
Recurrent Fallopian Tube Clear Cell Adenocarcinoma
Recurrent Fallopian Tube Endometrioid Adenocarcinoma
Recurrent Fallopian Tube High Grade Serous Adenocarcinoma
Recurrent Fallopian Tube Mucinous Adenocarcinoma
Recurrent Fallopian Tube Transitional Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Drug: Cediranib Maleate
Procedure: Computed Tomography
Procedure: Computed Tomography with Contrast
Procedure: Echocardiography
Procedure: Magnetic Resonance Imaging
Biological: Durvalumab
Procedure: Multigated Acquisition Scan
Drug: Paclitaxel
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Drug: Topotecan Hydrochloride
Drug: Olaparib

First Posted Date: 2021-02-05

Last Posted Date: 2025-01-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 120

Registration Number: NCT04739800

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Memorial Medical Center, Modesto, California, United States
🇺🇸
Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States

and more 389 locations

Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors

Phase 2

Active, not recruiting

Conditions: Mismatch Repair Proficient Colorectal Cancer
Pancreatic Adenocarcinoma
Leiomyosarcoma

Interventions: Biological: Durvalumab
Drug: Olaparib
Drug: Cediranib

First Posted Date: 2019-02-22

Last Posted Date: 2024-03-15

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 90

Registration Number: NCT03851614

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Phase 2

Active, not recruiting

Conditions: Endometrioid Adenocarcinoma
Stage IV Uterine Corpus Cancer AJCC v8
Endometrial Adenocarcinoma
Endometrial Mixed Cell Adenocarcinoma
Endometrial Serous Adenocarcinoma
Endometrial Undifferentiated Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspirate
Procedure: Bone Marrow Biopsy
Drug: Cediranib
Drug: Capivasertib
Drug: Cediranib Maleate
Biological: Durvalumab
Procedure: Computed Tomography
Procedure: Echocardiography
Drug: Olaparib
Procedure: Multigated Acquisition Scan

First Posted Date: 2018-09-07

Last Posted Date: 2025-01-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 288

Registration Number: NCT03660826

Locations: 🇺🇸
Jupiter Medical Center, Jupiter, Florida, United States
🇺🇸
Sacred Heart Hospital, Pensacola, Florida, United States
🇺🇸
Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States

and more 764 locations

Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib

Phase 2

Completed

Conditions: Ovarian Neoplasms

Interventions: Drug: Paclitaxel
Drug: Cediranib
Drug: Olaparib

First Posted Date: 2017-10-19

Last Posted Date: 2025-01-10

Lead Sponsor: Mario Negri Institute for Pharmacological Research

Target Recruit Count: 123

Registration Number: NCT03314740

Locations: 🇮🇹
Spedali Civili di Brescia, Brescia, BS, Italy
🇮🇹
Istituto Oncologico Veneto (IOV), Padova, PD, Italy
🇮🇹
Arcispedale Santa Maria Nuova, Reggio Emilia, RE, Italy

and more 3 locations

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Phase 2

Active, not recruiting

Conditions: Recurrent Glioblastoma

Interventions: Biological: Bevacizumab
Drug: Cediranib
Drug: Cediranib Maleate
Drug: Olaparib

First Posted Date: 2016-11-28

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT02974621

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States

and more 24 locations

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Extensive Stage Lung Small Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cediranib
Drug: Cediranib Maleate
Drug: Cisplatin
Drug: Etoposide
Drug: Olaparib

First Posted Date: 2016-09-14

Last Posted Date: 2023-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 9

Registration Number: NCT02899728

Locations: 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

and more 21 locations

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Castration-Resistant Prostate Carcinoma
Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation
Stage IV Prostate Adenocarcinoma AJCC v7
Metastatic Prostate Carcinoma
Prostate Adenocarcinoma With Neuroendocrine Differentiation
Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation

Interventions: Drug: Cediranib
Drug: Olaparib

First Posted Date: 2016-09-09

Last Posted Date: 2024-08-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 90

Registration Number: NCT02893917

Locations: 🇺🇸
Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States

and more 13 locations

A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer

Not Applicable

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Cediranib
Drug: Olaparib

First Posted Date: 2016-02-12

Last Posted Date: 2022-05-09

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 34

Registration Number: NCT02681237

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Phase 2

Active, not recruiting

Conditions: Fallopian Tube Clear Cell Adenocarcinoma
Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube Serous Adenocarcinoma
Fallopian Tube Transitional Cell Carcinoma
Fallopian Tube Undifferentiated Carcinoma
Ovarian Clear Cell Adenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Seromucinous Carcinoma
Ovarian Serous Adenocarcinoma
Ovarian Transitional Cell Carcinoma

Interventions: Procedure: Computed Tomography
Drug: Cediranib
Procedure: Magnetic Resonance Imaging
Drug: Cediranib Maleate
Drug: Paclitaxel
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Other: Questionnaire Administration
Drug: Olaparib
Drug: Topotecan
Drug: Topotecan Hydrochloride

First Posted Date: 2015-07-20

Last Posted Date: 2024-07-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 587

Registration Number: NCT02502266

Locations: 🇺🇸
West Penn Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
Pacific Gynecology Specialists, Seattle, Washington, United States
🇺🇸
Women's Cancer Center of Seattle, Seattle, Washington, United States

and more 397 locations

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Metastatic Pancreatic Adenocarcinoma
Metastatic Triple-Negative Breast Carcinoma
Stage III Breast Cancer AJCC v7
Stage III Lung Small Cell Carcinoma AJCC v7
Stage IIIA Breast Cancer AJCC v7
Stage IIIC Breast Cancer AJCC v7
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Stage IV Lung Non-Small Cell Cancer AJCC v7
Triple-Negative Breast Carcinoma

Interventions: Other: 18F-Fluoromisonidazole
Drug: Cediranib Maleate
Other: Laboratory Biomarker Analysis
Drug: Olaparib
Procedure: Positron Emission Tomography

First Posted Date: 2015-07-15

Last Posted Date: 2024-08-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 122

Registration Number: NCT02498613

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States

and more 13 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy